NCT02363946View on ClinicalTrials.gov

A Study of ARC-AAT in Healthy Volunteer Subjects and Patients With Alpha-1 Antitrypsin Deficiency (AATD)

PHASE1TerminatedINTERVENTIONAL
Enrollment

65

Participants

Timeline

Start Date

February 28, 2015

Primary Completion Date

November 30, 2016

Study Completion Date

November 30, 2016

Conditions
Alpha-1 Antitrypsin Deficiency
Interventions
DRUG

ARC-AAT Injection

RNA interference-based, liver-targeted therapeutic

OTHER

Placebo

0.9 % normal saline

DRUG

Diphenhydramine

Diphenhydramine 50 mg p.o. was administered 2 hours (±30 minutes) pre-dose as antihistamine pre-treatment.

Trial Locations (4)

3004

Nucleus Network Ltd, Melbourne

Unknown

Universitatsklinikum des Saarlandes, Homburg

2333ZA

Leiden University Medical Center, Leiden

B15 2WB

Queen Elizabeth Hospital, Edgbaston

Sponsors
All Listed Sponsors
lead

Arrowhead Pharmaceuticals

INDUSTRY